Bioceres Crop Solutions Corp Stock Price, News & Analysis

Bioceres Crop Solutions Corp. (BIOX) reported a 71% increase in revenues for 1Q23, totaling $127.1 million, compared to pro forma figures from 1Q22. Gross profit rose 52% to $51.4 million, while Adjusted EBITDA nearly doubled, reaching $24.5 million. The growth was driven by strong sales of micro-beaded fertilizers and biological products. A significant agreement with Syngenta Seedcare aims to enhance global inoculant growth, with a minimum profit share of $23 million per year. Despite a severe drought in Argentina, management remains optimistic about future growth.

Bioceres Crop Solutions Corp. (NASDAQ: BIOX) will host a conference call on November 10, 2022, at 8:30 a.m. ET to discuss its first quarter results for the period ending September 30, 2022. CEO Federico Trucco, CFO Enrique Lopez Lecube, and Head of Investor Relations Paula Savanti will lead the discussion, followed by a Q&A session. Investors can join via a toll-free number and access the call through a webcast. A replay will be available until November 15, 2022.

Syngenta Seedcare has partnered with Bioceres Crop Solutions (NASDAQ: BIOX) to exclusively commercialize its biological seed treatment solutions globally. This collaboration, stemming from a productive 20-year relationship, aims to accelerate the registration of existing products while jointly developing new solutions. The biological seed treatment market is expected to grow from $0.6 billion in 2020 to $1.6 billion by 2030. The agreement will enhance the availability of sustainable farming solutions while focusing on key markets like Brazil and China.

Bioceres Crop Solutions Corp. (NASDAQ: BIOX) reported strong financial results for the fourth quarter and fiscal year ended June 30, 2022. The fourth quarter saw a 44% increase in comparable revenues to $104.1 million, while full fiscal year revenues rose 62% to a record $319.3 million. HB4 Wheat revenues of $12.4 million marked a 94% increase YoY. Gross profit for the quarter was $41.4 million, a 32% increase, and Adjusted EBITDA reached $61.9 million, up 24%.

Successful mergers and ongoing regulatory approvals for HB4 products further bolster the company’s growth prospects.

Bioceres Crop Solutions Corp. (NASDAQ: BIOX) announced a conference call on September 8, 2022, at 8:30 a.m. ET to discuss its fourth quarter and fiscal year results for the period ending June 30, 2022. The call will feature key executives, including CEO Federico Trucco and CFO Enrique Lopez Lecube, and will include a Q&A session. A press release with detailed results will precede the call, and a replay will be available until September 13, 2022.

Bioceres Crop Solutions Corp. (NASDAQ: BIOX) has finalized capital commitments related to its merger with Marrone Bio Innovations, issuing secured guaranteed convertible notes worth $55 million with a 4-year maturity at an interest rate of 9%. The proceeds will address financial obligations of ProFarm Group and support merger synergies. Additionally, Bioceres issued new secured notes for $24.4 million to cover remaining convertible notes from 2020. Both note issuances aim to enhance operational efficiency while maintaining a strong financial structure.

Bioceres Crop Solutions Corp. (NASDAQ: BIOX) will participate in the Canaccord Genuity 42nd Annual Growth Conference from August 8-11, 2022, in Boston, MA. Key executives, including Chairman Federico Trucco and CFO Enrique Lopez Lecube, will conduct one-on-one meetings to discuss the company’s recent acquisition of Marrone Bio Innovations and HB4® Wheat and Soy approvals on August 10-11. Bioceres will also present on August 11 from 11:00-11:25 AM ET. For more details, visit the conference website or contact investor relations.

Bioceres Crop Solutions Corp. (NASDAQ: BIOX) announced the successful integration of Marrone Bio Innovations, Inc. (NASDAQ: MBII), valued at approximately $207 million. The merger, approved with 99.74% of votes on July 8, 2022, enhances Bioceres's position in sustainable agricultural solutions. MBI will operate as ProFarm, integrating its operational capabilities while leveraging expertise from former key employees. Changes in leadership include the addition of MBI directors to Bioceres's Board. This acquisition aims to foster a carbon-neutral agricultural landscape through innovative biological solutions.

Bioceres Crop Solutions Corp. (NASDAQ: BIOX) announced the FDA's conclusion of its evaluation of HB4® Wheat, indicating no further safety questions. This marks a crucial step toward commercialization in the U.S., pending USDA approval. The United States ranks fifth in wheat production, with HB4® Wheat already authorized in Argentina and recent approvals in Brazil, Colombia, Australia, and New Zealand. The HB4® technology significantly boosts wheat yields by 20% in water-limited conditions, promoting sustainable agricultural practices.